DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20183236

Effectiveness of allopurinol on triglyceride levels in hyperuricemic patients

Nermina Žiga, Fahir Bečić, Mirza Dedić

Abstract


Background: In this clinical pharmacological research, we dealt with the action of allopurinol on triglyceride levels in hyperuricemic patients.

Methods: The study included 40 hyperuricemic patients, of both genders and different age groups, that were sorted by comorbid diagnoses in several subgroups. All patients were clinically treated in the period of three years both at UCC Sarajevo, and P.I. General Hospital "Abdulah Nakaš" Sarajevo. All clinical measurements were carried out using standard IFCC methods with the appropriate analysers.

Results: The study was based on mean triglyceride levels before and after three and six months of treatment with allopurinol. It was found out that the mean triglyceride levels were not significantly different from the reference values prior to treatment (p = 0.846) and after three months of therapy (p=0.153). In contrast, after six months of treatment, triglyceride levels significantly increased compared to the reference values. In patients with a diagnosis of gout and metabolic syndrome, triglycerides were statistically significantly increased during the six months of observation. A statin group of patients showed a statistically significant increase in triglyceride levels after three months of therapy (p = 0.032), while, after six months their levels had decreased (p = 0.029). In patients with diabetes mellitus type II, triglycerides rose after three months of treatment (p = 0.039) and retained the same level after six months of observation.

Conclusions: The analysis shows that the use of allopurinol has an effect on triglyceride levels in hyperuricemic patients.


Keywords


Allopurinol, Hyperuricemia, Triglycerides

Full Text:

PDF

References


Vrbovac B. et al. Internal Medicine: Textbook. 4th ed. Zagreb: Naklada Ljevak;2008:1322-1326.

Zilva JF. Pannall PR. Mayne PD. Clinical Chemistry in Diagnosis and Treatment. Zagreb: Školska knjiga. 1992:379-388.

Antón FM. Puig JG. Ramos T. González P. Ordas J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17β (E2) on the renal handling of urate. Metabolism-Clinical and Experimental. 1986 Apr 1;35(4):343-8.

Walker R. Edwards C. Clinical Pharmacy and Therapeutics. 2nd ed. Zagreb: Grafički zavod. 2004:247-347.

Pušeljić S. Milas V. Hyperuricemia and hypouricemia-diagnosis and threatment. Paediatria Croatica. Supplement. 2009 Jan 1;1(53):178.

Zjačić-Rotkvić V. Katalinić D. Berković M. Metabolic insulin resistance and purine metabolism. Medicus. 2004 Nov 15;13(2_Diabetes mellitus):51-6.

Chen LY. Zhu WH. Chen ZW. Dai HL. Ren JJ. Chen JH. et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593-98.

Lin JD. Chiou WK. Chang HY. Liu FH. Weng HF. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism. 2007;56(6):751-56.

Rathmann W. Haastert B. Icks A. Giani G. Roseman JM. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol. 2007;22(7):439-45.

Yoo TW. Sung KC. Shin HS. Kim BJ. Kim BS. Kang JH. et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69(8):928-33.

Balasubramanian T. Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose. insulin. true triglyceride. and total cholesterol levels in Wistar rats. ScientificWorld J. 2003;3:930-36.

Nakagawa T. Hu H. Zharikov S. Tuttle KR. Short RA. Glushakova O. et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625-31.

Heimbach EJ. Bowden RG. Griggs JO. Beaujean AA. Doyle EI. Doyle R. The effects of lowering uric acid levels using allopurinol on components of metabolic syndrome. Cardiol Res. 2012;3(2):80-6.